Literature DB >> 7524376

Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.

O Ben-Izhak1, P Stark, R Levy, R Bergman, C Lichtig.   

Abstract

In order to determine epithelial markers in malignant melanoma in routinely processed paraffin sections and to compare the staining of primary (cutaneous) malignant melanomas and their metastases, we stained formalin-fixed paraffin sections of 13 primary and 18 metastatic malignant melanomas using the streptavidin-biotin peroxidase method by antibodies to S-100, vimentin, HMB-45, polyclonal carcinoembryonic antigen (CEA), monoclonal CEA, cytokeratins (CAM 5.2 and broad-spectrum CKKES), and epithelial membrane antigen (EMA). All primary and most metastatic malignant melanomas showed positive staining with anti-S-100, HMB-45, and anti-vimentin. Reactivity with polyclonal CEA was observed in 15 (48%) of the 31 lesions; 14 of them were metastatic. No lesion was reactive with monoclonal CEA. Significant cytokeratin (CK) staining was evident in only three (9.7%) lesions (all metastatic), which also stained specifically with anti-CK 18. EMA was observed only focally in two (6.5%) lesions. There was no correlation between epithelial markers staining of the primary tumours and their metastases. All lesions with CK or EMA staining showed concomitant extensive staining for S-100, HMB-45, and vimentin. We conclude that (a) polyclonal CEA staining in malignant melanoma is not rare and is probably due to CEA-related molecules; (b) significant CK reactivity is rare and related to simple CK, such as CK 18; (c) epithelial marker reactivity is more common in metastases of malignant melanomas and is not correlated to the reactivity in their primary tumors. Considering our results and reports of positive S-100, vimentin, and HMB-45 in epithelial tumors, a wide panel of antibodies is recommended for the study of undifferentiated tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524376     DOI: 10.1097/00000372-199406000-00003

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  11 in total

1.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

2.  PD-L1 Detection on Circulating Melanoma Cells.

Authors:  Joseph W Po; Yafeng Ma; Bavanthi Balakrishnar; Daniel Brungs; Farhad Azimi; Adam Cooper; Erin Saricilar; Vinay Murthy; Paul de Souza; Therese M Becker
Journal:  Methods Mol Biol       Date:  2021

3.  Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.

Authors:  Ryan C Romano; Jodi M Carter; Andrew L Folpe
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

4.  S100A6 expression and function in human osteosarcoma.

Authors:  Xiaoji Luo; Katie A Sharff; Jin Chen; Tong-Chuan He; Hue H Luu
Journal:  Clin Orthop Relat Res       Date:  2008-07-09       Impact factor: 4.176

5.  The evaluation of malignant mucosal melanoma of nasal cavity with a rare occasion.

Authors:  Ahmet H Kepekci; Cenk Kig; Gul I Gundogan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-08-10

6.  Expression of EpCAM in uveal melanoma.

Authors:  Danilo N Odashiro; Alexandre N Odashiro; Patrícia R Pereira; Katyanne Godeiro; Emilia Antecka; Sebastian Di Cesare; Miguel N Burnier
Journal:  Cancer Cell Int       Date:  2006-11-24       Impact factor: 5.722

7.  Tumor with the features of both squamous cell carcinoma and melanoma (melanocarcinoma).

Authors:  Elise Kochoumian; Viktoryia Kazlouskaya; Aaron Mangold; Karan Lal; Sandra Maia-Cohen; Dirk M Elston
Journal:  Indian Dermatol Online J       Date:  2015 May-Jun

8.  Rare Occurrence of an Intraocular Choroidal Solitary Fibrous Tumor/Hemangiopericytoma.

Authors:  Lorenzo Rinaldo; Sarah Chao Ying Xu; Scott D Eggers; Diva R Salomão; John J Chen; Aditya Raghunathan
Journal:  Ocul Oncol Pathol       Date:  2017-12-16

Review 9.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

Review 10.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.